kneat.com (TSE:KSI) Hits New 12-Month High - Still a Buy?

Shares of kneat.com, inc. (TSE:KSI - Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as C$6.87 and last traded at C$6.84, with a volume of 166540 shares trading hands. The stock had previously closed at C$6.57.

Wall Street Analyst Weigh In

Several equities analysts have commented on KSI shares. Cibc World Mkts raised shares of kneat.com to a "strong-buy" rating in a research report on Tuesday, October 29th. CIBC set a C$6.00 price objective on kneat.com and gave the company an "outperform" rating in a research note on Tuesday, October 29th.

kneat.com Trading Up 2.4 %

The company's fifty day moving average is C$6.16 and its two-hundred day moving average is C$5.28. The stock has a market cap of C$598.56 million, a price-to-earnings ratio of -43.50, a PEG ratio of 597.67 and a beta of 1.08. The company has a quick ratio of 1.50, a current ratio of 1.47 and a debt-to-equity ratio of 95.14.

kneat.com (TSE:KSI - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported C$0.01 EPS for the quarter, beating analysts' consensus estimates of C($0.05) by C$0.06. kneat.com had a negative net margin of 31.19% and a negative return on equity of 51.13%. During the same period in the prior year, the firm posted ($0.05) EPS. On average, research analysts predict that kneat.com, inc. will post -0.12 EPS for the current fiscal year.

kneat.com Company Profile

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.